Clinical impact of novel treatment strategies

[1]  K. Mori,et al.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.

[2]  Edward S. Kim,et al.  IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer , 2001, Seminars in oncology.

[3]  R. Figlin,et al.  Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[5]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[6]  F. Shepherd,et al.  A randomised phase II study of gemcitabine/cisplatin alone and with herceptin in patients with HER2-positive non-small cell lung cancer (nsclc) , 2001 .

[7]  R. Herrmann,et al.  Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Cherrington,et al.  The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. , 2001, Blood.

[9]  M. Piccart,et al.  Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Jett,et al.  Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Kris,et al.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  J. Adlard.  Thalidomide in the treatment of cancer , 2000, Mayo Clinic health letter.

[13]  H. Kantarjian,et al.  Current role of thalidomide in cancer treatment , 2000, Current opinion in oncology.

[14]  Y. Hosomi,et al.  Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. , 2000, Lung cancer.

[15]  Y. Kawahito,et al.  Meloxicam inhibits the growth of non-small cell lung cancer. , 2000, Anticancer research.

[16]  T. Chevalier,et al.  Gene therapy with intratumor (IT) injection of an adenovirus expressing the IL2 gene (rAd-IL2) in lung cancer: Results of a phase I study , 2000 .

[17]  M. Mihm,et al.  A phase I study of vaccination with lethally irradiated, autologous nonsmall cell lung carcinoma cells engineered by adenoviral mediated gene transfer to secrete human granulocyte-macrophage colony stimulating factor , 2000 .

[18]  M. Kris,et al.  Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR) , 2000 .

[19]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[20]  R. Salgia,et al.  Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571 , 2000, Oncogene.

[21]  G. Tortora,et al.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  H. Modjtahedi,et al.  Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase‐9 expression and in vitro invasion , 2000, International journal of cancer.

[23]  S. Albelda,et al.  Gene Therapy for Lung Disease: Hype or Hope? , 2000, Annals of Internal Medicine.

[24]  B. Fingleton,et al.  Matrix metalloproteinases: biologic activity and clinical implications. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Norton,et al.  Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. Bowden,et al.  Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  F. Khuri,et al.  Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Chou,et al.  Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. , 1999, Cancer research.

[29]  B. Barlogie,et al.  Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.

[30]  E K Rowinsky,et al.  Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  N. Ferrara.  Molecular and biological properties of vascular endothelial growth factor , 1999, Journal of Molecular Medicine.

[32]  G. Fontanini,et al.  The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression. , 1999, Human pathology.

[33]  F. Khuri,et al.  Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. , 1999, Journal of the National Cancer Institute.

[34]  Y. Yatabe,et al.  Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  Y. Yarden,et al.  The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Poen,et al.  Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. , 1999, Cancer research.

[37]  A. Petri,et al.  Gene therapy for lung cancer. , 1999, Lung cancer.

[38]  J. Kern,et al.  The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. , 1998, Lung cancer.

[39]  A. Ristimäki,et al.  Expression of cyclooxygenase-2 in human lung carcinoma. , 1998, Cancer research.

[40]  W. Hong,et al.  Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. , 1998, Journal of the National Cancer Institute.

[41]  L. Kaiser,et al.  Cancer chemotherapy using suicide genes. , 1998, Surgical oncology clinics of North America.

[42]  W. Figg,et al.  Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. , 1998, Biochemical pharmacology.

[43]  A. Tong,et al.  Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung. , 1998, American journal of clinical oncology.

[44]  L. Matrisian,et al.  Changing views of the role of matrix metalloproteinases in metastasis. , 1997, Journal of the National Cancer Institute.

[45]  R. D'Amato,et al.  Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. , 1997, Experimental eye research.

[46]  S. Albelda.  Gene therapy for lung cancer and mesothelioma. , 1997, Chest.

[47]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[48]  P. Comoglio,et al.  Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. , 1996, British Journal of Cancer.

[49]  K. Gatter,et al.  Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis. , 1996, Anticancer research.

[50]  T. Nakajima,et al.  Expression of c‐met/HGF Receptor in Human Non‐small Cell Lung Carcinomas in vitro and in vivo and Its Prognostic Significance , 1996, Japanese journal of cancer research : Gann.

[51]  W. Hong,et al.  Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer. , 1996, Nature Medicine.

[52]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. , 1996, Seminars in cancer biology.

[53]  F. Askari,et al.  Antisense-oligonucleotide therapy. , 1996, The New England journal of medicine.

[54]  S. Bunting,et al.  Vascular endothelial growth factor, a specific regulator of angiogenesis , 1996, Current opinion in nephrology and hypertension.

[55]  J. Folkman.  Clinical Applications of Research on Angiogenesis , 1995 .

[56]  N. Rosen,et al.  A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. , 1995, Cancer research.

[57]  M. Tsao,et al.  Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. , 1995, Cancer research.

[58]  J. Folkman,et al.  A strategy to discover circulating angiogenesis inhibitors generated by human tumors. , 1995, Cancer research.

[59]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[60]  N. Ibrahim,et al.  Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. , 1995, Journal of the National Cancer Institute.

[61]  A. Levitzki,et al.  Tyrosine kinase inhibition: an approach to drug development. , 1995, Science.

[62]  C. Halbert,et al.  Adeno-associated virus vectors transduce primary cells much less efficiently than immortalized cells , 1995, Journal of virology.

[63]  G. Nicolson,et al.  c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. , 1994, Cancer research.

[64]  S. Rodenhuis,et al.  C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. , 1994, The Journal of clinical investigation.

[65]  J. Baselga,et al.  Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. , 1993, Cancer research.

[66]  R L Smith,et al.  Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. , 1993, Science.

[67]  A. Gazdar,et al.  Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. , 1993, Journal of the National Cancer Institute.

[68]  J. Carmichael,et al.  Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. , 1993, Journal of the National Cancer Institute.

[69]  S. Rodenhuis,et al.  The ras oncogenes in human lung cancer. , 1990, The American review of respiratory disease.

[70]  M. L. Le Beau,et al.  A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[71]  S. Bates,et al.  Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells. , 1989, Molecular endocrinology.

[72]  B. Teicher,et al.  Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies , 2004, Cancer Chemotherapy and Pharmacology.

[73]  A. Wozniak,et al.  Chronic Oral Administration of CI-994: A Phase I Study , 2004, Investigational New Drugs.

[74]  P. LoRusso,et al.  Preclinical antitumor activity of CI-994 , 2004, Investigational New Drugs.

[75]  J. Roth,et al.  Gene therapy for cancer: what have we done and where are we going? , 1997, Journal of the National Cancer Institute.

[76]  Tsung-Teh Wu,et al.  Extracellular matrix expression in metastasizing and nonmetastasizing adenocarcinomas of the lung. , 1997, Human pathology.

[77]  Z. Ram,et al.  In situ delivery of suicide genes for cancer treatment. , 1994, European journal of cancer.

[78]  A. Ullrich,et al.  Growth factor receptor tyrosine kinases. , 1988, Annual review of biochemistry.

[79]  G. Carpenter,et al.  Receptors for epidermal growth factor and other polypeptide mitogens. , 1987, Annual review of biochemistry.